T-cell prolymphocytic leukaemia

T-cell prolymphocytic leukaemia (T-PLL) is a rare and unusual haematological malignancy.

It represents around 2% of all mature lymphocytic leukaemias in adults over the age of 30 1. It usually affects older adults with an average age at presentation being around 65 years. There may be a slight male predominance.

While there can be a potentially-wide clinical spectrum, many patients tend to present with hepatosplenomegaly and generalised lymphadenopathy.

It is characterised by the proliferation of small- to medium-sized prolymphocytes of post-thymic origin. There can be a wide spectrum where involvement of the peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin can occur.

The imaging spectrum can also be variable with hepatosplenomegaly and generalised lymphadenopathy being common. Pleural effusions and cutaneous lesions may also be detectable in a small number of patients.

Clinical course is often very aggressive with poor response to conventional chemotherapy. Poor survival rates have usually been reported with the potential long-term curative treatment being haematopoietic stem cell transplantation.  Treatment with purine analogues and alemtuzumab have been reported to have significantly higher response rates and improved survival 2,3.

Share article

Article information

rID: 43973
Tag: stub
Synonyms or Alternate Spellings:
  • T-PLL
  • T cell prolymphocytic leukemia
  • T cell prolymphocytic leukemia (T-PLL)

Support Radiopaedia and see fewer ads

Updating… Please wait.

Alert accept

Error Unable to process the form. Check for errors and try again.

Alert accept Thank you for updating your details.